

Supplementary Table 1. Metabolic pathways of CYP substrate drugs and comparison of predicted and observed drug-drug interaction caused by rifampicin and rifabutin.

Abbreviations

a.m., active moiety; BCRP, breast cancer resistance protein; CR, contribution ratio of cytochrome P450 (see main text); NAT, N-acetyltransferase; OATP, Organic-anion-transporting-polypeptides; PE, prediction error of R_{AUC} (predicted R_{AUC} - observed R_{AUC}); PGP, P-glycoprotein; R_{AUC} , ratio of areas under the concentration-time curve (see main text), R_{AUC} OBS, observed R_{AUC} ; R_{AUC} PRED, predicted R_{AUC} ; UGT, UDP-glucuronosyltransferase.

CR values were taken from the DDI-predictor website: www.ddi-predictor.org

Non-CYP pathways were retrieved from drugbank (<https://go.drugbank.com>) and transformer application databases (<https://bioinformatics.charite.de/transformer>)

Target interval of predicted R_{AUC} is 0.5 to 2 times the observed R_{AUC} .

Dienogest	0.6	0	0	0	0					0.17	0.18	0.06	44		
Disopyramide	0.22	0	0	0	0					0.33	0.37	0.12	45		
doravirine	0.78	0	0	0	0			0.5	0.37	-0.26	0.12	0.14	0.17	46	
Erlotinib	0.47	0	0	0	0.35						0.25	0.2	-0.20	47	
esaxerenone	0.33	0	0	0	0						0.31	0.28	-0.10	48	
Estradiol valerate	0.26	0	0	0	0						0.56	0.33	-0.41	49	
Ethinylestradiol	0.26	0	0	0	0		X		0.65	0.64	-0.02	0.34	0.33	-0.03	44
Etravirine	0.44	0	0	0	0				0.63	0.37	-0.41				50
Fesoterodine a.m.	0.53	0.47	0	0	0						0.23	0.2	-0.13	51	
Flibanserin	0.82	0	0	0.18	0						0.05	0.12	1.40	52	
Fluvastatin	0	0	0.8	0	0	X					0.5	0.51	0.02	53	
Fostamatinib a.m.	0.44	0	0	0	0						0.25	0.23	-0.08	54	
Gefitinib	0.39	0.5	0	0	0						0.17	0.25	0.47	55	
Gemigliptin	0.56	0	0	0	0						0.2	0.19	-0.05	56	
Gliben-Glyburide	0	0	0.63	0	0						0.61	0.57	-0.07	57	
Glimepiride	0	0	0.99	0	0		X				0.34	0.45	0.32	58	
Ibrutinib (fasten)	0.98	0	0	0	0						0.11	0.12	0.09	59	
Imatinib	0.35	0	0	0	0	X					0.26	0.27	0.04	60	
Isavuconazole	0.86	0	0	0	0						0.1	0.13	0.30	61	
Ivacaftor	0.9	0	0	0	0						0.11	0.13	0.18	62	
laquinimod	0.66	0	0	0	0						0.2	0.16	-0.20	63	
lorlatinib	0.31	0	0	0	0						0.15	0.3	1.00	64	
Losartan	0	0	0.4	0	0		X	X			0.69	0.67	-0.03	65	
Lurasidone	0.72	0	0	0	0						0.19	0.15	-0.21	66	
Mefloquine	0.44	0	0	0	0						0.32	0.23	-0.28	67	
Midazolam	0.91	0	0	0	0		X		0.31	0.34	0.10	0.12	0.12	0.00	68,106
Midazolam	0.91	0	0	0	0		X				0.04	0.12	2.00	69	
naldemedine	0.62	0	0	0	0						0.17	0.17	0.00	70	
Naloxegol	0.95	0	0	0	0						0.11	0.12	0.09	71	

Nateglinide	0	0	0.48	0	0							0.76	0.63	-0.17	72		
neratinib	0.89	0	0	0	0			X				0.12	0.13	0.08	73		
Netupitant	0.51	0	0	0	0				X			0.19	0.2	0.05	74		
Nifedipine	0.72	0	0	0	0							0.08	0.15	0.88	75		
Nilotinib	0.67	0	0	0	0			X				0.2	0.16	-0.20	76		
Olaparib	0.67	0	0	0	0				X			0.13	0.16	0.23	77		
Palbociclib	0.49	0	0	0	0				X			0.15	0.21	0.40	78		
Palonosetron	0.05	0.2	0	0	0							0.81	0.72	-0.11	74		
Phenytoin	0	0	0.72	0.19	0	X		X	X			0.5	0.37	-0.26	79		
Pitolisant	0.13	0.52	0	0	0							0.5	0.5	0.00	80		
Ponatinib	0.32	0	0	0	0				X			0.37	0.29	-0.22	81		
Praziquantel	0.49	0	0	0.18	0							0.15	0.18	0.20	82		
Prednisolone	0.18	0	0	0	0				X			0.49	0.42	-0.14	83		
Prednisolone	0.18	0	0	0	0				X			0.72	0.42	-0.42	84		
Propranolol	0	0.51	0	0.26	0.23			X				0.37	0.41	0.11	85		
Ramelteon	0	0	0	0.42	0.58							0.2	0.28	0.40	86		
Regorafenib	0.18	0	0	0	0				X			0.5	0.42	-0.16	87		
Ribociclib	0.93	0	0	0	0							0.11	0.12	0.09	88		
Ruxolitinib	0.35	0	0	0	0							0.3	0.27	-0.10	89		
Saquinavir	0.58	0	0	0	0	X		X	X	X	0.53	0.45	-0.15		90		
Simvastatin	0.97	0	0	0	0	X			X			0.09	0.12	0.33	68		
Simvastatin	0.97	0	0	0	0	X			X			0.14	0.12	-0.14	91		
Siponimod	0.12	0	0.77	0	0							0.43	0.35	-0.19	92		
Sunitinib	0.42	0	0	0	0							0.25	0.24	-0.04	93		
suvorexant	0.75	0	0	0	0				X			0.12	0.15	0.25	94		
Tasimelteon	0.15	0	0	0	0.85							0.11	0.3	1.73	95		
Telithromycin	0.49	0	0	0	0	X						0.14	0.21	0.50	96		
Tizanidine	0	0	0	0	0.97							0.46	0.42	-0.09	97		
Tolbutamide	0	0	0.89	0	0			X			0.63	0.63	0	0.36	0.48	-0.33	106,13

Tolvaptan	0.81	0	0	0	0					0.13	0.14	0.08	98
Triazolam	0.93	0	0	0	0					0.05	0.12	1.40	99
Ulipristal	0.86	0	0	0	0					0.1	0.13	0.30	100
Vandetanib	0.09	0	0	0	0		X			0.6	0.59	-0.02	101
Voriconazole	0.31	0	0	0.68	0			0.22	0.22	0			40
Vortioxetine	0.24	0.6	0	0.13	0								102
zanubrutinib	0.8	0	0	0	0								105
Zolpidem	0.4	0	0	0	0.35								103
Zopiclone	0.44	0	0	0	0								104
Mean PE (SD)										0.11 (0.22)		0.13 (0.50)	
Percentage of R _{AUC} in target interval										0.91		0.94	